CEO Yu-Hsin Lin highlighted the completion of Phase III PHOENIX trial enrollment with 530 subjects for geographic atrophy and the completion of the Phase III DRAGON trial for Stargardt's disease, ...

Moss reiterated, "We expect to have the manuscript and the peer-reviewed publication filed on the MINDFuL trial sometime this month...We expect to have the end of Phase II meeting with the FDA to take ...

Rachel King is a trailblazer in biotech, a venture capitalist turned co-founder and CEO, now turned industry leader. As CEO of the Biotechnology Innovation Organization (BIO), King has focused in ...

INmune Bio is working with the FDA to define a path forward for the therapy based on these results. According to the company, its cash position stood at approximately $27.7 million as of September 30, ...